Benign prostatic hyperplasia and evidence based medicine: Its approach in clinical practice;Hiperplasia prostática benigna y medicina basada en la evidencia: Su aproximación a la práctica clínica

Medicina Clinica

Volumn 114, Issue SUPPL. 2, 2000, Pages 96-104

  Carballido Rodríguez, Joaquín A ^a   Rodríguez Vallejo, José M ^b   Del Llano Señaris, Juan E ^c  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Universidad Pontificia Comillas   (Spain)

Author keywords

Benign prostatic hyperplasia; Evidence based medicine

Indexed keywords

AGED; ARTICLE; EVIDENCE BASED MEDICINE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SPAIN; STANDARD;

AGED; EVIDENCE-BASED MEDICINE; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 0033657536     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Partin AW. Ethiology of benign prostatic hyperplasia. En: Lepor H, editor. Prostate diseases. Filadelfia: W.B. Saunders Co., 2000; 7: 95-105.
2. Chute CG, Panser LA, Girman CI, Oesterling JE, Guess HA, Jacobsen SI et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1996; 150: 85-89.
3. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hyperplasia in the community. Lancet 1991; 338: 469-471.
4. Hald T. Urodynamics in benign prostatic hyperplasia. A survey. Prostate 1989; 2 (Supl): 69-77.
5. Girman CJ, Guess HA. Epidemiology of benign prostatic hyperplasia. En: Lepor H, editor. Prostatic diseases. Filadelfia: W.B. Saunders Co., 2000; 9: 116-126.
6. Stoevalaar HJ, Van de Beek C, Capsparie AF, McDonnell J, Nijs HG. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference? J Urol 1999; 161: 133-138.
7. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
8. Isaacs JT, Coffey DS. Ethiology and disease process of benign prostatic hyperplasia. Prostate 1989; 2 (Supl): 33-50.
9. thAnnual Meeting. Dallas, Office of Education: 1999.
10. Wennberg JE, Mulley AGJ, Hanley D, Timothy RP, Fowler JR, Jr, Roos NP et al. An assessment of prostatectomy for benign urinary tract obstruction: geographic variations and the evaluation of medical care outcomes. JAMA 1988; 25: 3027-3030.
11. Holthgrawe ML. The medical management of lower urinary tract symptoms and benign prostatic hyperplasia. Urol Clin North Am 1998; 25: 555-569.
12. Girman CJ, Jacobsen SJ, Guess HA Oesterling JE. Natural history of prostatism: relationship among symptoms, prostate volume, and peak urinary flow rate. J Urol 1995; 153: 1510-1515.
13. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1995; 22: 247-261.
14. Jacobsen SJ, Girman CH, Guess HA. Natural history of prostatism: longitudinal changes in voiding symptoms in community-dwelling men. J Urol 1996; 155: 595-600.
15. Jacobsen SJ, Girman CJ, Guess HA, Oesterling HE, Llieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 1995; 155: 477-481.
16. Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-1557.
17. Vela R, Martín JM, Calahorra FJ, Damián J, Hernández A, Boyle P. Validaciön cultural y lingüïstica en castellano del Baremo Internacional de Sïntomas Prostáticos (I-PSS). Actas Url Esp 1994; 18: 841-847.
18. Badía X, García-Losa M, DalRé R. Ten-language translation and harmonization of the International Prostate Symptom Score (IPSS). Developing a methodology for multinational clinical trials. Eur Urol 1997; 31: 129-140.
19. th International Consultation on BPH. Plymouth UK: Plymbridge Distributors Ltd., 1997; 23-59.
20. Norman RW, Nickel JC, Fishj D, Pickett SN. Prostate-related symptoms in Canadian' men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 1994; 74: 542-550.
21. Sagnier PP, McFarlane G, Teillac P, Botto H, Richard F, Boyle P. Result of an Epidemiological Survey Employing a Modified American Urological Association Index for Benign Prostatic Hyperplasia in France. J Urol 1994; 151: 1266-1270.
22. Bosch JLHR, Hop WCJ, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urol 1995; 46 (Supl A): 34-40.
23. Homma Y, Kawabe K, Tsukamoto T. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the International Prostate Symptom Score. Int Urol 1997; 4: 40-46.
24. Chicharro JA, Burgos R, Sánchez JJ, Del Rosal JM, Rodero R, Rodríguez Vallejo JM. Prevalence of benign prostatic hyperplasia in Spanish men 40 years older. J Urol 1998; 159: 878-882.
25. Hunter DJW, Berra-Unamuno A, Martin Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years or older. J Urol 1996; 155: 1965-1970.
26. INE. Servidor TEMPUS del Instituto Nacional de Estadistica (INE). Mayo de 1998.
27. Girman CJ, Epstein RS, Jacobsen SJ. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825-831.
28. Girman CJ, Jacobsen SJ, Tsukamoto T. Lower urinary tract symptoms and quality of life in four international community studies. Urology 1998; 51: 428-436.
29. Hunter DJW, McKee CM, Black NA. Urinary symptoms: prevalence and severity in British men aged 55 and over. J Epidemiol Community Health 1994; 48: 569-575.
30. Epstein RS, Deverka PA, Chute CG. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 1431-1435.
31. Garraway WM, Russell EBAW, Lee RJ, Collins GN, McKelvie GB, Hehir M et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 318-321.
32. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess MA et al. Natural history of prostatism: risk factor for acute urinary retention. J Urol 1997; 158: 481-487.
33. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline Number 8, AHCPR Publications N094-0582. Rockville, Maryland: Agency for Health Care Policy and Research, Public Health Service. United States Department of Health and Human Services, febrero de 1994.
34. Guess HA. Population based studies of benign prostatic hyperplasia. En: Kirby R, Boyle P, Griffiths K, editores. Handbook of benign prostatic hyperplasia. Londres: Isis Medical Media, 1996; 117-124.
35. Meigs JB, Bary Y, MJ. Natural history of benign prostatic hyperplasia. En: Kirby R, McConnell J, Fitzpatrick J et al, editores. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media, 1996; 125-135.
36. Albertsen P, Pellisier J, Lowaf et al. Economic analysis of finasteride. A model based approach using data from Proscar long-term efficacy and safety study. Clinical Therapeutics 1999; 21: 1006-1024.
37. Cockerman P, Finder S, Ries AJ, Ptyk RP. A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. Pharmacoeconomics 1997; 11: 550-565.
38. Boyle EA, Asua J, Albisu A. Hiperplasia benigna de próstata. Variabilidad de práctica y guía de actuación basada en la evidencia científica. Aten Primaria 1999; 23: 142-156.
39. Pozo F. La medicina basada en la evidencia. Una perspectiva desde la clínica. Med Clin (Barc) 1999; (Supl 1): 112: 12-16.
40. Gol Freixa JM. Bienvenidos a la medicina basada en la evidencia. En: Evidence Based Medicine Work Group. La medicina basada en la evidencia. Guias del usuario de la literatura médica. Barcelona: Doyma, 1997; 5-14.
41. De la Cámara A. Manual de medicina basada en la evidencia. Elementos para su desarrollo y aplicación en atención primaria. Madrid: Jarpyo Eds. S.A., 1998.
42. Sackettr DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine. How to practice and teach. EBM Londres: Churchill Livingstone, 1997.
43. Brotons C. Medicina basada en la evidencia: un reto para el siglo xxi. Med Clin (Barc) 1998; 111: 552-557.
44. Expósito J, Aguado E, Rodríguez del Castillo M. Tratamientos oncológicos basados en la evidencia científica. Med Clin (Barc) 1998; 112. 465-469.
45. Gol Freixa JM, Del Llano JE. El fenómeno de la medicina basada en la evidencia. Med Clin (Barc) 1999; 112 (Supl 1): 3-8.
46. Del Llano JE, Menen R. Asistencia sanitaria basada en la evidencia. Med Clin (Barc) 1999; 112 (Supl 1): 90-96.
47. Berra de Unamuno A, Calahorra L, Lázaro Y, De Mercado P. Cirugía de la hiperplasia benigna de próstata. Estándares de uso apropiado. Madrid: Ministerio de Sanidad y Consumo - Instituto de Salud Carlos III. Agenda de Evaluación de Tecnologías Sanitarias (AETS); julio de 1996. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo, junio de 1996.
48. Carballido J. El ensayo clínico en hiperplasia prostática benigna: ?dónde estamos? Rev Clin Esp 1999; 199 (monográfico 2): 48-57.
49. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urol 1996; 48: 398-405.
50. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC, and Writting Committee. Transuretral prostatectomy: immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-247.
51. Caine M. Alfa-adrenergic blockers for the treatment of benign prostatic . hyperplasia. Urol Clin North Am 1990; 17: 641.
52. Monda JE, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5-alfa reductase inhibitors and alfa-adrenergic antagonists. Mayo Clin Proc 1993; 68: 670-679.
53. Lepor H. The role of alpha 1 selective blockade in the management of benign prostatic hyperplasia. J Vasc Med Biol 1990; 2: 254-261.
54. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 1999; 53: 671-678.
55. Lowe FC, Dreikorn K, Borkowsdi A, Braeckman J, Denis L, Ferrari P et al. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 1998; 37: 187-193.
56. McConnell JD, Bruxkewitz R, Walsa P, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-563.
57. Marberger MJ. Long term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998; 51: 677-686.
58. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1995; 22: 375.
59. Raz S, Ziegle M, Caine M. Pharmacologic receptors in the prostate. Br J Urol 1975; 27: 193.
60. Hieble JP, Bylund DB, Clarke DE. International Union of Pharmacologys. Recommendation for nomenclature of alpha 1 adrenoreceptors: consensus update. Pharmacol Rev 1995; 47: 276-270.
61. Kirby RS, Pool JL. Alpha adrenoreceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 1997; 80: 521-532.
62. Narayan P, Tewari A. Overview of alpha-blocker for benign prostatic hyperplasia. Urology 1998; 51 (Supl 4i: 38-45.
63. Chapple CR, Baert L, Thind P et al. Tamsulosin, 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 1997; 32: 462-470.
64. Buzelin JM, Fonteyne E, Kantturi M et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstructions (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 1997; 80: 597-605.
65. De Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact of safety and well-being. Eur Urol 1998; 34 (supl 2): 18-28.
66. Oxman AD, Sackett DL, Guyatt GH, for the Evidence-Based Medicine Working Group. User's guide to the medical literature, I: how to get started? JAMA 1993; 270: 2093-2095.
67. th International Consultation on Benign Prostatic Hyperplasia. Proceedings. París, 1997.
68. Carballido JA, Rodríguez Reina G. Hiperplasia prostática benigna: evaluación clínica, diagnóstico y alternativas terapéuticas. Medicine (Madr) 1997; 7: 2897-2906.
69. Guirman CJ, Panser LA, Chute CG. Natural history of prostatism: urinary flow rates in a community-based study. J Urol 1993; 150: 887-892.
70. Chalmers TC, Mata RJ, Smith H Jr, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977; 297: 1091-1096.
71. Wilt T, Ishani AL, Stark G, McDonald R, Mulrow L, Lan J. Serenoa replus for treatment of benign prostatic hyperplasia. En: Protocol for a Cochrane Review. The Cochrane Library, Issue 4, Oxford Update Software, 1998.
72. Bonfill X, Etxeverry C, Marti J, Glutting JP, Urrutia G, Padevall M. El desarrollo de la colaboración Cochrane española. Med Clin (Barc) 1999; 112 (Supl 1): 17-20.
73. Spealman MJ. Who should be treated and how? Evidence-based medicine in symptomatic BPH. Eur Urol 1999; 36 (Supl 3): 40-51.